SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-000239
Filing Date
2023-01-05
Accepted
2023-01-05 16:19:12
Documents
14
Period of Report
2023-01-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rani-20230105.htm   iXBRL 8-K 59868
2 EX-99.1 rani-ex99_1.htm EX-99.1 21013
3 GRAPHIC img125106939_0.jpg GRAPHIC 30251
  Complete submission text file 0000950170-23-000239.txt   248919

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rani-20230105_pre.xml EX-101.PRE 10303
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rani-20230105.xsd EX-101.SCH 2493
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rani-20230105_lab.xml EX-101.LAB 14018
8 EXTRACTED XBRL INSTANCE DOCUMENT rani-20230105_htm.xml XML 4939
Mailing Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131
Business Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131 (408) 457-3700
Rani Therapeutics Holdings, Inc. (Filer) CIK: 0001856725 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40672 | Film No.: 23511570
SIC: 2834 Pharmaceutical Preparations